Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Phosphatase and actin regulator 3 (PHACTR3) is a regulatory subunit for protein phosphatase 1 (PP1) that binds both actin and the catalytic subunit of PP1, inhibiting PP1 activity[1][2][3]. PHACTR3 is associated with the nuclear scaffold in proliferating cells and is particularly enriched in neurons, where it regulates cytoskeletal dynamics, dendritic morphology, and axon elongation through independent actin-binding and PP1-binding domains[3][5]. The protein promotes cell spreading and motility by modulating actin polymerization and is involved in neural as well as undifferentiated or transformed cell function[3]. Alterations of PHACTR3, including hypermethylation and deregulated expression, have been implicated in the development of cancers such as colorectal and non-small cell lung cancer, suggesting a role in tumorigenesis and potential utility as a biomarker for early cancer detection[3][5]. No direct therapeutic drugs or known pharmacological inhibitors target PHACTR3 as of now.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Phosphatase and actin regulator 3 (PHACTR3).